Fig. 3.
Fig. 3. RT-PCR analysis of the DDX10-NUP98 and NUP98-DDX10 chimeric transcripts in four inv(11) patients with de novo or secondary myeloid malignancies. (A) Detection of RT-PCR products by electrophoresis. The DDX10-NUP98 and NUP98-DDX10 chimeric transcripts were amplified with primers DF26 and NR17, and primers NF2 and DR27, respectively (see Fig 1C and D). Pt1, Pt2, Pt3, Pt4: RT-PCR amplified patient RNA samples. Pt1 (−), Pt2 (−): patient 1 and 2 PCR product without reverse transcription. Ct: RT-PCR amplified normal peripheral blood RNA. Arrows indicate the detected fusion transcripts. (B) Sequences of the junctions of the NUP98-DDX10 chimeric transcripts (DDBJ/EMBL/GenBank accession nos. AB000267 and AB000268). Two RT-PCR products (c and d) were sequenced. Nucleotide sequences and predicted amino acid sequences around the junctions are shown. The vertical arrows indicate the junction points of the two genes.

RT-PCR analysis of the DDX10-NUP98 and NUP98-DDX10 chimeric transcripts in four inv(11) patients with de novo or secondary myeloid malignancies. (A) Detection of RT-PCR products by electrophoresis. The DDX10-NUP98 and NUP98-DDX10 chimeric transcripts were amplified with primers DF26 and NR17, and primers NF2 and DR27, respectively (see Fig 1C and D). Pt1, Pt2, Pt3, Pt4: RT-PCR amplified patient RNA samples. Pt1 (−), Pt2 (−): patient 1 and 2 PCR product without reverse transcription. Ct: RT-PCR amplified normal peripheral blood RNA. Arrows indicate the detected fusion transcripts. (B) Sequences of the junctions of the NUP98-DDX10 chimeric transcripts (DDBJ/EMBL/GenBank accession nos. AB000267 and AB000268). Two RT-PCR products (c and d) were sequenced. Nucleotide sequences and predicted amino acid sequences around the junctions are shown. The vertical arrows indicate the junction points of the two genes.

Close Modal

or Create an Account

Close Modal
Close Modal